Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154940 | 0.90 | DPP4 (0.41) | DPP4DPP7DPP8DPP9GRM2 | |
| SCHEMBL4161389 | 0.90 | DPP4 (0.37) | DPP4DPP7DPP8 | |
| SCHEMBL12856008 | 0.88 | DPP4 (0.48) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL16716340 | 0.88 | DPP4 (0.48) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL9318901 | 0.80 | PLG (0.67) | SLC1A2SLC1A1 | |
| SCHEMBL21553762 | 0.80 | DPP4 (0.39) | DPP4DPP7 | |
| SCHEMBL8597594 | 0.77 | ANPEP (0.51) | — | |
| SCHEMBL22862958 | 0.77 | — | — | |
| SCHEMBL2408337 | 0.72 | — | — | |
| SCHEMBL8097665 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153649-B | Allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3433234-B1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3433234-B1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20190337910-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3433234-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9926285-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926285-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926285-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9840481-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840481-B2 | Allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| WO-2017165256-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165256-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | LABORATORIOS SALVAT, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7423172-B2 | Tyrosine derivatives as PPAR-γ-modulators | LABORATORIOS SALVAT, S.A. (ES) | 2008-09-09 | — | — | US | disclosed |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | LABORATORIES SALVAT, S.A. (ES) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088438-A1 | NEW TYROSINE DERIVATIVES AS PPARy MODULATORS | PPARG, PPARD, TYRO3 | DPP4 2321/4885DPP7 3181/4885DPP8 2494/4885 |
| US-20190337910-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | DPP4 3539/4885DPP7 1337/4885DPP8 2184/4885 |
| US-20180030007-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | DPP4 3406/4885DPP7 1397/4885DPP8 2264/4885 |
| US-20070276043-A1 | Tyrosine Derivatives As Ppar-Gamma-Modulators | PPARG, PPARD, PPARA | DPP4 2441/4885DPP7 3367/4885DPP8 2895/4885 |
| US-20170275260-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | DPP4 3406/4885DPP7 1397/4885DPP8 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.